Vancive Medical Technologies and Dukal have announced an agreement for the distribution of the Vancive BeneHold absorbent wound dressing range in the US and Canada.
The BeneHold range includes the thin absorbent wound dressing, the standard hydrocolloid dressing and the bordered hydrocolloid dressing with odor control.
Vancive president and general manager Howard Kelly noted this agreement between Vancive Medical Technologies and Dukal brings together Vancive’s unique technologies and know-how with Dukal’s specialized sales team.
"DUKAL’s products are already used in traditional wound and skin care, and by adding the BeneHold Absorbent Wound Dressing range, they significantly broaden the continuum of care within their product offering," Kelly added.
The BeneHold absorbent wound dressings manage lightly to moderately exuding chronic and acute wounds. Products in the BeneHold absorbent wound dressing portfolio are constructed of a self-adherent wound contact layer and a smooth, water-resistant polyurethane top film that acts as a barrier to external contaminants and bacteria. The dressings exhibit superior fluid handling capacity, yet are thinner and more conformable to enhance patient comfort.
The thin absorbent dressings are based on Vancive’s proprietary technology, TASA (Thin Absorbent Skin Adhesive). At only 0.1mm in thickness, TASA has the capacity to manage fluid in excess of traditional thin hydrocolloids. Furthermore, the dressings are transparent and allow for site visibility up to seven days. The Bordered Hydrocolloid Dressing with Odor Control is formulated with organic, non-cytotoxic cyclodextrins that capture odor molecules to help increase patient confidence.
BeneHold and TASA are trademarks of Avery Dennison.